- Oral presentation
- Open Access
Lipid modifying therapy and aortic wall thickness regression by Magnetic Resonance Imaging (MRI): the plaque follow up study by the National Institute of Aging (NIA)
© Godoy et al; licensee BioMed Central Ltd. 2010
- Published: 21 January 2010
- Magnetic Resonance Imaging
- Lipid Lowering Therapy
- Future Cardiovascular Event
Aortic atherosclerotic plaque is associated with increased risk of future cardiovascular events. Magnetic resonance imaging (MRI) is a precise non-invasive tool for accurate measurements of aortic wall thickness in patients with advanced atherosclerosis and allows for monitoring plaque regression.
The purpose of this study was to assess the relationship between changes in aortic wall thickness measured by MRI in response to lipid modifying therapy.
114 participants age >65 years were enrolled in a double blinded randomized trial as part of the NIA Plaque study. Participants were randomly assigned to two treatment groups; one receiving simvastatin and niacin and other receiving simvastatin and placebo. Baseline MRI was performed on all participants using a 1.5-Tesla scanner. Follow-up MRI exams were done every 6 months for 18 months. Axial images of 3 segments of the thoracic aorta (ascending, arch and descending) were obtained using a double inversion recovery black blood fast spin-echo sequence with ECG-gating. 0.1 mmol/kg of gadodiamide contrast was given intravenously. Post contrast T1-weighted images were used to evaluate the changes in vessel wall thickness and lumen diameter over the course of lipid therapy. Paired t test and multivariable regression were used for data analyses.
(p = 0.01). However, no difference in the plaque regression was noticed between the two treatment groups in the study.
Our study demonstrates that thoracic aorta plaque regression can be detected accurately by MRI after 12 months of lipid lowering therapy and was associated with the increase in HDL and decrease in LDL levels. The addition of Niacin to simvastatin compared to simvastatin alone did not show any added benefit to the thoracic aorta plaque regression.
This article is published under license to BioMed Central Ltd.